Problems with Numbers in Decision Aids for Prostate-specific Antigen Screening: A Critical Review.
作者信息
Carlsson Sigrid V, Vickers Andrew J, Gonsky Jason P, Hay Jennifer L, Hu Jim C
机构信息
Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Department of Urology, Institute of Clinical Sciences, Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden.
Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
出版信息
Eur Urol. 2021 Mar;79(3):330-333. doi: 10.1016/j.eururo.2020.11.011. Epub 2020 Dec 9.
Abstract
摘要
相似文献
1
Problems with Numbers in Decision Aids for Prostate-specific Antigen Screening: A Critical Review.前列腺特异性抗原筛查决策辅助工具中的数字问题：一项批判性综述。
Eur Urol. 2021 Mar;79(3):330-333. doi: 10.1016/j.eururo.2020.11.011. Epub 2020 Dec 9.
2
Primary Care Providers' Intended Use of Decision Aids for Prostate-Specific Antigen Testing for Prostate Cancer Screening.初级保健提供者对用于前列腺癌筛查的前列腺特异性抗原检测决策辅助工具的预期用途。
J Cancer Educ. 2019 Aug;34(4):666-670. doi: 10.1007/s13187-018-1353-5.
3
Web-Based Versus Usual Care and Other Formats of Decision Aids to Support Prostate Cancer Screening Decisions: Systematic Review and Meta-Analysis.基于网络的决策辅助工具与常规护理及其他形式的决策辅助工具对前列腺癌筛查决策的支持：系统评价与荟萃分析
J Med Internet Res. 2018 Jun 26;20(6):e228. doi: 10.2196/jmir.9070.
4
Prostate Cancer Screening Patient Decision Aids: A Systematic Review and Meta-analysis.前列腺癌筛查患者决策辅助工具：系统评价和荟萃分析。
Am J Prev Med. 2018 Dec;55(6):896-907. doi: 10.1016/j.amepre.2018.06.016. Epub 2018 Oct 16.
5
Prostate-specific antigen dynamics and prostate cancer diagnosis.前列腺特异性抗原动态变化与前列腺癌诊断
Eur Urol. 2009 Nov;56(5):761-2; discussion 763. doi: 10.1016/j.eururo.2009.07.048. Epub 2009 Aug 4.
6
American Urological Association (AUA) guideline on prostate cancer detection: process and rationale.美国泌尿外科学会 (AUA) 前列腺癌检测指南：流程和原理。
BJU Int. 2013 Sep;112(5):543-7. doi: 10.1111/bju.12318.
7
The Era of Prostate-specific Antigen-based Personalized Prostate Cancer Screening Has Only Just Begun.基于前列腺特异性抗原的个性化前列腺癌筛查时代才刚刚开始。
Eur Urol. 2015 Aug;68(2):214-5. doi: 10.1016/j.eururo.2015.01.031. Epub 2015 Feb 11.
8
Prostate-specific antigen screening for prostate cancer: a decision-analytical perspective.前列腺癌的前列腺特异性抗原筛查：决策分析视角
BJU Int. 2007 Sep;100(3):486-8. doi: 10.1111/j.1464-410X.2007.07055.x.
9
Re: Improving the Specificity of Screening for Lethal Prostate Cancer Using Prostate-Specific Antigen and a Panel of Kallikrein Markers: A Nested Case-Control Study.回复：使用前列腺特异性抗原和一组激肽释放酶标志物提高致命性前列腺癌筛查特异性：一项巢式病例对照研究。
J Urol. 2015 Aug;194(2):393-4. doi: 10.1016/j.juro.2015.05.066. Epub 2015 May 18.
10
Toward a smarter prostate cancer screening program.迈向更智能的前列腺癌筛查计划。
Eur Urol. 2015 Oct;68(4):598-9. doi: 10.1016/j.eururo.2014.05.002. Epub 2014 May 15.
引用本文的文献
1
The impact of mpMRI-targeted vs systematic biopsy on the risk of prostate cancer downgrading at final pathology.mpMRI 靶向与系统活检对最终病理前列腺癌降级风险的影响。
World J Urol. 2024 Apr 22;42(1):248. doi: 10.1007/s00345-024-04963-w.
2
Provider Perceptions of an Electronic Health Record Prostate Cancer Screening Tool.医疗机构对电子健康记录前列腺癌筛查工具的看法。
Appl Clin Inform. 2024 Mar;15(2):282-294. doi: 10.1055/s-0044-1782619. Epub 2024 Apr 10.
3
Shared decision-making before prostate cancer screening decisions.前列腺癌筛查决策前的共同决策。
Nat Rev Urol. 2024 Jun;21(6):329-338. doi: 10.1038/s41585-023-00840-0. Epub 2024 Jan 2.
4
The prognostic value of high-grade prostate cancer pattern on MRI-targeted biopsies: predictors for downgrading and importance of concomitant systematic biopsies.MRI靶向活检中高级别前列腺癌模式的预后价值：降级的预测因素及同期系统活检的重要性
World J Urol. 2021 Sep;39(9):3315-3321. doi: 10.1007/s00345-021-03631-7. Epub 2021 Feb 20.
本文引用的文献
1
Reconsidering the Trade-offs of Prostate Cancer Screening.重新审视前列腺癌筛查的权衡取舍。
N Engl J Med. 2020 Jun 18;382(25):2465-2468. doi: 10.1056/NEJMsb2000250.
2
Clinical Decision Making: Communicating Risk and Engaging Patients in Shared Decision Making.临床决策：沟通风险并让患者参与共同决策。
Ann Intern Med. 2020 May 19;172(10):688-692. doi: 10.7326/M19-3495. Epub 2020 Apr 21.
3
Decision Aids for Prostate Cancer Screening Choice: A Systematic Review and Meta-analysis.前列腺癌筛查选择的决策辅助工具：一项系统评价与荟萃分析。
JAMA Intern Med. 2019 Aug 1;179(8):1072-1082. doi: 10.1001/jamainternmed.2019.0763.
4
Systematic Review of the Volume-Outcome Relationship for Radical Prostatectomy.根治性前列腺切除术的体积-结局关系的系统评价。
Eur Urol Focus. 2018 Dec;4(6):775-789. doi: 10.1016/j.euf.2017.03.008. Epub 2017 Apr 6.
5
Decision making and cancer.决策与癌症。
Am Psychol. 2015 Feb-Mar;70(2):105-18. doi: 10.1037/a0036834.
6
A simple schema for informed decision making about prostate cancer screening.一个用于前列腺癌筛查知情决策的简单模式。
Ann Intern Med. 2014 Sep 16;161(6):441-2. doi: 10.7326/M14-0151.
7
Providing information about options in patient decision aids.提供患者决策辅助工具中各种选择的相关信息。
BMC Med Inform Decis Mak. 2013;13 Suppl 2(Suppl 2):S4. doi: 10.1186/1472-6947-13-S2-S4. Epub 2013 Nov 29.
8
Toward Minimum Standards for Certifying Patient Decision Aids: A Modified Delphi Consensus Process.迈向患者决策辅助工具认证的最低标准：一种改进的德尔菲共识过程。
Med Decis Making. 2014 Aug;34(6):699-710. doi: 10.1177/0272989X13501721. Epub 2013 Aug 20.
9
Screening for prostate cancer with prostate-specific antigen testing: American Society of Clinical Oncology Provisional Clinical Opinion.用前列腺特异性抗原检测进行前列腺癌筛查：美国临床肿瘤学会临时临床意见。
J Clin Oncol. 2012 Aug 20;30(24):3020-5. doi: 10.1200/JCO.2012.43.3441. Epub 2012 Jul 16.
10
Health literacy and shared decision making for prostate cancer patients with low socioeconomic status.社会经济地位较低的前列腺癌患者的健康素养与共同决策
Cancer Invest. 2001;19(7):684-91. doi: 10.1081/cnv-100106143.
Zotero 插件